Cardozo Journal of International and Comparative Law
Abstract
The note examines the role of patent systems in the biotechnology industry, particularly in gene therapy, comparing the approaches of the EU and the U.S. It highlights how differences in patentability standards, such as the exclusion of treatment methods in the EU versus broader protections in the U.S., impact innovation and investment. The analysis emphasizes the need for balanced patent policies that foster innovation while addressing ethical concerns.
Disciplines
Antitrust and Trade Regulation | Food and Drug Law | Intellectual Property Law | Law | Science and Technology Law
Recommended Citation
Nada Jain,
To Patent or Not to Patent: Gene Therapy in the European Union and the United States,
4
Cardozo J. Int'l & Comp. L.
103
(1996).
Available at:
https://larc.cardozo.yu.edu/cjicl/vol4/iss1/8
Included in
Antitrust and Trade Regulation Commons, Food and Drug Law Commons, Intellectual Property Law Commons, Science and Technology Law Commons